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ABSTRACT 
 
This study evaluated the short-term cost-effectiveness of the Patient Empowerment 
Programme (PEP) for diabetes mellitus in Hong Kong. Propensity score matching was used 
to select a matched group of PEP and non-PEP subjects. A societal perspective was adopted 
to estimate the cost of PEP. The outcome measures were the cumulative incidence of all-
cause mortality and diabetic complication over a five-year follow-up and the number needed 
to treat (NNT) to avoid one event. The incremental cost-effectiveness ratio (ICER) of cost per 
event avoided was calculated using the PEP cost per subject multiplied by the NNT. The PEP 
cost per subject from the societal perspective was US$247. There was a significantly lower 
cumulative incidence of all-cause mortality (2.9% vs 4.6%, p<0.001), any diabetic 
complication (9.5% vs 10.8%, p=0.001) and CVD events (6.8% vs 7.6%, p=0.018), in the 
PEP group. The costs per death from any cause, DM complication or case of CVD avoided 
were US$14,465, US$19,617 and US$30,796, respectively. The extra amount allocated to 
running PEP was small and it appears cost-effective in the short-term as an addition to RAMP.   
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INTRODUCTION 
Self-management education programmes were shown to be effective in systematic reviews, 
but whether such programmes are also cost-effective is important to health care decision 
makers to allocate limited resources efficiently. Our recent systematic review identified 12 
cost-effective studies published between January 2003 and September 2015 but none was 
carried out on an Asian population who might have different response to education 
interventions for culture and practical reasons.1   
A Patient Empowerment Programme (PEP) for Diabetes Mellitus (DM) was launched by the 
Hong Kong (HK) Hospital Authority (HA) in 2010, aiming to enhance subjects’ disease-
specific knowledge and self-management skills, promote self-efficacy and modify lifestyles. 
Detailed descriptions of the programme are available elsewhere.2-8 Apart from the PEP, the 
HA introduced a multi-disciplinary Risk Assessment and Management Programme (RAMP) 
in 2009 to provide regular check-ups and complication screening to all DM subjects in public 
general outpatient clinics (GOPCs) that provide primary care services.9 Over 90% of the PEP 
subjects currently participate in RAMP serving as routine clinical practice. We therefore 
interested to evaluate the cost-effectiveness of PEP as additional to RAMP using empirical 
cost and effectiveness data from a cohort with up to five years of follow up.   
 
MATERIALS AND METHODS 
Evaluating the five-year effectiveness of PEP 
We selected subjects with DM who had joined RAMP on or before 31 March 2012 and have 
attended at least one PEP session within 180 days of their first RAMP assessment as the PEP 
group, while those who had not joined PEP by 30 Nov 2015 were defined as the non-PEP 
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group. We excluded subjects who had any pre-defined diabetic complications including 
cardiovascular disease (CVD), diabetic retinopathy (DR), nephropathy or neuropathy; and 
those who had specialist medical clinic attendances within 6 months on or before their 
baseline visit; and those did not have complete data at baseline. Propensity score matching 
was used to match the two groups on socio-demographic factors, clinical baseline measures, 
clinical characteristics, and health service utilization at baseline. 
The outcome used was the first occurrence of any CVD complication, DR (including sight 
threatening diabetic retinopathy), end stage renal disease (ESRD), neuropathy or mortality 
from any cause during the five-year follow up period.  
Costing of PEP  
A societal perspective was adopted to estimate the cost of the programme which included 
NGO resource costs, HA administrative costs as well as costs to the community and to 
subjects attending PEP.  We converted them to a per subject cost and the final PEP cost per 
subject was the sum of the above four categories. All costs are originally calculated in 
HK$ and converted into US$ for reporting (1US$=7.8HK$). 
A structured questionnaire was distributed to the NGOs in all seven geographical clusters in 
HK to collect data on expenditures in setting up in the first year of operation, and in running 
PEP each year. HA administrative costs were obtained from the HA Finance Division to 
estimate the costs spent on PEP at head office and cluster office.  
The set-up cost for NGOs and HA was divided by the number of subjects who attended at 
least one PEP session in that cluster, while the ongoing cost was divided by the number of 
subjects in that cluster in the corresponding financial year and then was averaged across the 
years. Finally, these per cluster costs were averaged across all clusters. 
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The NGOs reported on the time of volunteers spent on PEP. These were annualized and 
valued at the hourly wages of the specific staff, if noted, or the median hourly wage for the 
Hong Kong population.10  The use of NGO’s own, or other unpaid, venues for PEP were 
valued based on the rental cost of paid venues reported in that year. These costs were 
summed and divided by the corresponding number of subjects, and averaged across clusters 
and years.  
A self-administered questionnaire was distributed to 475 subjects in all clusters to collect the 
travel cost and time used by subjects and accompanying person(s) attending the PEP. Time 
spent attending PEP sessions was measured as an average of 2.5 hours for disease-specific 
sessions and 2 hours for generic sessions and each participant attended on average four 
sessions with two disease-specific and two generic sessions for each subject and 6% of 
subjects had a companion. Travel and attendance time was valued using the median hourly 
wage for subjects and their companions.10 Co-payments were paid by some subjects but 
ignored as a transfer payment under the societal perspective.   
Statistical analysis  
The characteristics of the matched PEP and non-PEP groups were compared by independent 
t-test or chi-squared tests. Five-year cumulative incidence of the outcomes was calculated for 
each type of event and compared between the groups by chi-squared tests. All statistical 
analyses were performed in STATA 13 while the cost and cost-effectiveness analysis were 
done in excel. 
Cost-effectiveness Analysis 
Only the extra costs of PEP in additional to routine health care were considered since both 
groups attended RAMP. We did not discount the cost since the programme cost was onetime 
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cost only i.e. all present cost. The number needed to treat (NNT) to avoid one event over five-
year was estimated for outcomes which was significantly different between groups. The 
incremental cost-effectiveness ratio (ICER) was calculated using the PEP cost per subject 
multiplied by the NNT giving us cost per complication or death avoided during the study 
period. One-way sensitivity analysis was conducted to test the uncertainties surrounding the 
PEP cost per subject using the minimum to maximum values of costs reported by the NGOs. 
Effectiveness was tested with the 95% confidence interval (CI) for events of PEP groups 
constructed based on Poisson distribution.  
 
RESULTS 
Characteristics of the matched PEP and non-PEP groups 
After excluding ineligible subjects, there were 11,600 subjects in the PEP group remained for 
matching which yielded 11,581 matched pairs (Appendix 1). There were no significant 
differences between the matched groups (Appendix 2). 
Five-year effectiveness of PEP  
The mean follow-up for PEP and non-PEP groups was 53 and 55 months, respectively. There 
was a significantly lower cumulative incidence of all-cause mortality (2.9% vs 4.6%, 
p<0.001), any diabetic complication (9.5% vs 10.8%, p=0.001) and CVD events (6.8% vs 
7.6%, p=0.018), in the PEP group than in the non-PEP group (Appendix 3). There was no 
significant difference in the cumulative incidences of DR, ESRD or neuropathy.    
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PEP cost per subject 
The total societal PEP cost per subject was US$247 with a range across NGOs of US$191 to 
US$297 (Table 1). Among these 57% were the provider costs; 38% were the subjects’ and 
families’ costs; and, 5% were community costs. 
 
Cost-effectiveness of PEP 
The incremental cost of PEP versus non-PEP group was the programme cost above and NNT 
to avoid a death from any cause is 58, resulting in an ICER of US$14,465 per death (Table 2).  
The cost to avoid one CVD death was US$68,192. To avoid any DM complication, the NNT 
is 79 and this gives an ICER of US$19,617. The ICER to avoid a CVD event is US$30,796, 
to avoid a stroke is US$42,747 and to avoid a heart failure event is US$58,450. Varying the 
cost of the programme did not have a large impact on the ICERs, but varying the 
effectiveness may increase the ICER up to two times of the base case.  
 
DISCUSSION 
The estimated cost of PEP per subject was around US$128-US$256, depending on whether 
the subject costs were included or not. Of the NGO-ongoing cost, staff cost and other 
operating expense costs caused greatest variability while equipment and venue rentals did not 
cause a lot of variation. The variation in staff cost could be explained by different grades of 
staffs used, different number or working hours of staff used.       
The additional cost to avoid a death from any cause by PEP was US$14,465 (HK$112,827). 
A local estimate of the statistical value of life saved in HK was at least HK$10 million.11 By 
this measure, the cost to avoid one death was far below the value and so PEP could be 
Running title: CEA of PEP for T2DM 
8 
 
considered cost-effective. Diabetic complications are usually associated with extra health 
service costs. For example, one study in HK estimated the health service cost for subject with 
CVD was 2.88 to 7.04 times higher in event year and 1.33 to 2.43 times higher in subsequent 
year than subject without CVD.12 It would be expected that the PEP cost could be 
compensated for the reduction in health service utilization due to prevention of complications. 
In the current calculation of cost-effectiveness, we did not include the health service costs in 
the costing part to avoid double counting of the benefits in dollar values since it has already 
counted in the effectiveness part, i.e. reduction in complications.  
The advantage of this study was that the five-year follow-up period would allow us to 
observe the difference in development of diabetic complications between groups rather than 
only surrogate outcomes i.e. HbA1c, blood pressure which commonly used in other short-
term CEA studies. The comprehensive estimate of the programme cost in this study was also 
important for the quality of the cost-effectiveness findings. The limitation was that this study 
was not a RCT, therefore we need to be cautious of claiming the association of PEP on the 
reduced incidence as a causal association. As RCT is not always practical in a service setting, 
we generated two similar groups based on the characteristics for which we have data. The 
baseline characteristics of our matched groups were all comparable in demographic, clinical 
risk factors and health service utilization. Nonetheless we must admit to the possibility that 
the two groups may differ in some aspects which are not reflected in the variables we have. 
Our further analyses on changes in DM knowledge score and clinical measurements of the 
PEP group stratified by the number of PEP sessions showed an expected trend with larger 
improvement in knowledge and clinical risk factors from those who attended more sessions 
(Appendix 4). This supports the view that the association between PEP and the improved 
outcomes could be causal.  
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There have been a few studies on the cost-effectiveness of self-management education 
programmes but none were directly comparable to the PEP programme. Similar to our group 
based structured diabetes education programme in primary care setting, a programme named 
DESMOND in UK was found to be cost-effective from provider perspective with an ICER of 
£5,387 per QALY gained using a life-time model.13 Another programme also with diabetes 
group education structure in South Africa was shown to be cost-effective from societal 
perspective with an ICER of US$1,862 per QALY gained using a life-time model.14 Neither 
of these studies calculated the cost per complication or death prevented but both studies 
supported the cost-effectiveness of self-management education programmes which is 
consistent with our conclusion.      
In conclusion, the extra amount allocated to running PEP was not very great and it appears to 
be cost-effective over five years. This was a lifestyle education programme taken in addition 
to the routine care offered in the RAMP programme and, as others have shown, might be 
even more cost-effective when taking a life time horizon. 
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Table 1. Summary of average PEP costs per subject 
Costs 
Cost per subject Range 
(US$) (min to max) 
HA administration costs (excluding payments to NGOs) 53 NA 
Head office level (including  Head office Team, IT Development &  
Maintenance, Other Operating costs) 22  
    Cluster level (including Cluster Support Office) 31  
   
NGOs resources costs 88 43-139 
Set-up cost (staff, equipment and others) 5 1-12 
On-going cost 83 42-129 
Staff  69 39-87 
Venue rental 4 0-12 
Equipment 1 0-2 
Other operating expenses 9 1-49 
   
Costs to the society  13 2-46 
Cost of volunteers 8 0-33 
NGO’s own or unpaid venues 5 0-12 
   
Costs to subjects attending PEP 94 85-106 
Time cost for subjects in attending PEP sections 65  64-66 
Time cost for accompany person  in attending PEP secessions 4  1-7 
Travelling cost and time for subjects (2-way) 23  18-31 
Travelling cost and time for accompany person (2-way) 1  0.3-4 
Societal perspective: average PEP costs/subject 247 191-297 
Note: NA = not applicable; HA = Hospital Authority; NGO = Non-Governmental Organization 
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Table 2. Short-term cost-effectiveness of PEP versus non-PEP from a societal perspective 
Endpoint 
No. of observed events, 
n (%)  NNT 
ICER (Cost/event avoided) (US$) 
  
Non PEP 
(N=11581) 
PEP 
(N=11581) Base-case 
Sensitivity on 
cost* 
Sensitivity on 
effect** 
All deaths 536 (4.6%) 338 (2.9%)  58 14,465 11,143-17,389 12,238-17,683 
CVD deaths 72 (0.6%) 30 (0.3%)  276 68,192 52,532-81,979 54,310-91,607 
        
Any complication 
(CVD, DR, ESRD, 
Neuropathy) 
1245 
(10.8%) 
1099 
(9.5%)  79 19,617 15,112-23,583 13,575-35,349 
        
CVD events 875 (7.6%) 782 (6.8%)  125 30,796 23,724-37,023 19,377-74,995 
Stroke events 395 (3.4%) 328 (2.8%)  173 42,747 32,930-51,390 27,943-90,915 
Heart failure events 209 (1.8%) 160 (1.4%)  236 58,450 45,027-70,268 38,813-118,312 
CVD=Cardiovascular Disease; IHD= Ischaemic Heart Disease; DR=Diabetic Retinopathy; STDR=Sight Threatening Diabetic 
Retinopathy; ESRD= End Stage Renal Disease; NNT=number needed to treat; ICER=incremental cost-effectiveness ratio 
* PEP cost per subject was tested using the minimum to maximum values of costs reported by the NGOs.  
** 95% CI for events of PEP groups were constructed based on Poisson distribution. The minimum and maximum NNT were calculated 
using the 95% CI and to generate the range of ICERs  
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Appendix 1. Flowchart of subjects’ selection 
 
 
 
Note: RAMP= Risk Assessment and Management Programme; PEP =Patient Empowerment Programme; DM = Diabetes 
Mellitus; SOPC = Specialist Outpatient Clinic 
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Appendix 2. Demographic and Clinical Characteristics 
   Matched Before matching  
  p-value* PEP Non-PEP Non-PEP 
Socio-demographic characteristics     
N  11581 11581 84318 
Sex, n (%)     
  Female 0.474 6614 (57.1) 6560 (56.6) 45256 (53.7) 
  Male 4967 (42.9) 5021 (43.4) 39062 (46.3) 
Age, mean (SD) 0.196 63.1 (9.8) 63.3 (10.7) 64.3 (11.6) 
Current smoker, n (%) 0.921 894 (7.7) 886 (7.7) 9851 (11.7) 
Under CSSA, n (%) 0.285 1370 (11.8) 1423 (12.3) 12926 (15.3) 
Education      
  No formal education 
0.660 
1453 (12.6) 1444 (12.5) 16778 (19.9) 
  Primary 4575 (39.5) 4642 (40.1) 32122 (38.1) 
  Secondary 4797 (41.4) 4715 (40.7) 30627 (36.3) 
  Tertiary 756 (6.5) 780 (6.7) 4791 (5.7) 
HA clusters     
  A 
0.503 
1464 (12.6) 1523 (13.2) 11909 (14.1) 
  B 963 (8.3) 995 (8.6) 4391 (5.2) 
  C 2026 (17.5) 2053 (17.7) 8821 (10.5) 
  D 1237 (10.7) 1284 (11.1) 10732 (12.7) 
  E 1466 (12.7) 1421 (12.3) 22377 (26.5) 
  F 3886 (33.6) 3795 (32.8) 16685 (19.8) 
  G 539 (4.7) 510 (4.4) 9403 (11.2) 
     
Clinical characteristics     
Self-reported duration of DM, mean (SD) 0.536 6.6 (6.3) 6.6 (5.8) 7.8 (6.5) 
History of hypertension, n(%) 0.873 8274 (71.4) 8263 (71.4) 61953 (73.5) 
Use of anti-hypertensive drugs, n(%) 0.808 8691 (75.1) 8675 (74.9) 64307 (76.3) 
Use of lipid lowing drugs, n(%) 0.261 3789 (32.7) 3709 (32.0) 22111 (26.2) 
On oral anti-diabetic drug, n (%) 0.075 9651 (83.3) 9549 (82.5) 73436 (87.1) 
On insulin, n (%) 0.311 118 (1.0) 134 (1.2) 1294 (1.5) 
Chronic kidney disease, n (%) 0.513 1099 (9.5) 1070 (9.2) 11566 (13.7) 
Charlson's index 0.793 3.7 (1.1) 3.7 (1.2) 3.5 (1.3) 
         
BMI, kg/m2 0.202 25.6 (4.0) 25.5 (3.9) 25.5 (3.9) 
HbA1c, % 0.398 7.4 (1.3) 7.4 (1.4) 7.2 (1.3) 
Systolic blood pressure, mmHg 0.806 134.3 (17.8) 134.2 (16.9) 135.7 (17.5) 
Diastolic blood pressure, mmHg 0.532 75.8 (10.7) 75.7 (10.4) 74.9 (10.3) 
Total cholesterol to HDL ratio, mmol/L 0.911 4.0 (1.2) 4.0 (1.2) 4.1 (1.2) 
LDL-cholesterol, mmol/L 0.988 2.9 (0.8) 2.9 (0.8) 2.9 (0.8) 
Triglyceride, mmol/L  0.842 1.6 (0.9) 1.6 (1.1) 1.5 (1.0) 
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Health service utilization in the past 12 months     
A&E attendance, mean (SD) 0.744 0.31 (0.9) 0.32 (0.8) 0.34 (1.0) 
In-patient admission, mean (SD) 0.115 0.09 (0.4) 0.10 (0.4) 0.11 (0.4) 
GOPC attendance, mean (SD) 0.765 5.16 (2.4) 5.17 (2.6) 5.14 (2.3) 
SOPC attendance, mean (SD) 0.944 1.31 (2.4) 1.31 (2.6) 1.25 (2.5) 
CSSA=comprehensive social security assistance; PEP=patient empowerment programme; BMI = Body Mass Index ; HbA1c = Hemoglobin A1c; 
LDL-C = Low Density Lipoprotein - Cholesterol; HDL-C High Density Lipoprotein - Cholesterol; A&E= Accident and Emergency; GOPC = General 
Outpatient Clinic; SOPC = Specialist Outpatient Clinic;  
*by t-test or Chi2 test 
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Appendix 3. Five-year cumulative incidence of complications 
  
Cumulative number and incidence of complication 
events 
  
Non-PEP 
(N=11581) 
PEP 
 (N=11581) p-value 
    n % n %   
All deaths 536 4.6% 338 2.9% <0.001 
CVD deaths 72 0.6% 30 0.3% <0.001 
Cancer deaths 194 1.7% 137 1.2% 0.002 
Respiratory deaths 112 1.0% 46 0.4% <0.001 
       
Any complication 
(CVD, DR, ESRD, 
Neuropathy) 1245 10.8% 1099 9.5% 0.001 
      
 CVD events 875 7.6% 782 6.8% 0.018 
  IHD events 395 3.4% 380 3.3% 0.584 
  Stroke events 395 3.4% 328 2.8% 0.011 
  Heart failure events 209 1.8% 160 1.4% 0.010 
      
 DR events  321 2.8% 279 2.4% 0.082 
 STDR events 49 0.4% 47 0.4% 0.838 
         
 ESRD events 128 1.1% 121 1.0% 0.656 
 Neuropathy events 33 0.3% 23 0.2% 0.181 
CVD=Cardiovascular Disease; IHD= Ischaemic Heart Disease; DR=Diabetic Retinopathy; STDR=Sight 
Threatening Diabetic Retinopathy; ESRD= End Stage Renal Disease 
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Appendix 4. Pre and Post-programme knowledge score and change in clinical measurement over five years 
by number of sessions 
   No. of PEP session attended 
 Overall  
1 PEP 
session 
2 PEP 
sessions 
3 PEP  
sessions 
4 PEP 
sessions 
5 PEP 
sessions 
6 PEP 
sessions 
7 PEP 
sessions 
≥8 PEP 
sessions 
Knowledge score          
N 6325  199 1032 174 547 362 1160 2606 245 
  Pre 3.98  3.69 3.80 4.22 4.36 3.91 4.22 3.81 4.78 
  Post 7.38  6.41 6.48 6.47 6.95 7.14 7.65 7.84 7.82 
  Post - Pre 3.40*  2.72* 2.68* 2.25* 2.58* 3.23* 3.44* 4.02* 3.04* 
           
Clinical risk factors          
N 11581  1708 3328 552 908 588 1349 2718 430 
HbA1c (%)           
  Pre 7.38  7.41 7.42 7.27 7.42 7.40 7.28 7.40 7.22 
  Post** 6.98  7.05 7.01 6.93 6.94 6.95 6.84 7.01 6.90 
  Post - Pre -0.40*  -0.36* -0.41* -0.34* -0.48* -0.45* -0.44* -0.39* -0.32* 
SBP (mmHg)          
  Pre 134.26  133.86 133.78 134.62 135.49 133.93 135.55 133.86 135.52 
  Post** 129.42  130.03 129.81 128.68 128.32 128.68 128.92 129.79 127.48 
  Post - Pre -4.85*  -3.84* -3.97* -5.93* -7.17* -5.25* -6.63* -4.07* -8.03* 
DBP (mmHg)          
  Pre 75.83  75.68 75.70 76.08 75.89 76.60 76.33 75.13 78.93 
  Post** 71.86  71.82 71.97 71.91 72.13 71.79 71.90 71.44 73.22 
  Post - Pre -3.97*  -3.86* -3.73* -4.17* -3.76* -4.81* -4.43* -3.68* -5.71* 
LDL-C (mmol/l)          
  Pre 2.88  2.92 2.86 2.89 2.93 2.90 2.92 2.86 2.80 
  Post** 2.23  2.26 2.24 2.23 2.23 2.18 2.21 2.24 2.17 
  Post - Pre -0.65*  -0.65* -0.62* -0.66* -0.71* -0.72* -0.71* -0.62* -0.62* 
BMI (kg/m2)          
  Pre 25.58  25.60 25.60 25.69 25.32 25.37 25.54 25.56 26.29 
  Post** 25.35  25.42 25.42 25.40 25.05 25.19 25.32 25.23 26.07 
  Post - Pre -0.23*  -0.18* -0.19* -0.29* -0.26* -0.18* -0.22* -0.32* -0.21 
*p-value <0.05 by t-test 
**Clinical measurement at 60-month or last available record after intervention 
HbA1c = Hemoglobin A1c; SBP= Systolic Blood Pressure ; DBP= Diastolic Blood Pressure; LDL-C = Low Density Lipoprotein - Cholesterol;  
BMI = Body Mass Index; 
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Appendix 5. CHEERS checklist—Items to include when reporting economic evaluations of 
health interventions 
Section/item Item 
No 
Recommendation Reported on 
page No/ line 
No 
Title and abstract 
Title 1 Identify the study as an economic evaluation or use 
more specific terms such as “cost-effectiveness 
analysis”, and describe the interventions compared. Page 1 
Abstract 2 Provide a structured summary of objectives, perspective, 
setting, methods (including study design and inputs), 
results (including base case and uncertainty analyses), 
and conclusions. Page 2 
Introduction 
Background and 
objectives 
3 Provide an explicit statement of the broader context for 
the study.  
Present the study question and its relevance for health 
policy or practice decisions. Page 3 
Methods 
Target population and 
subgroups 
4 Describe characteristics of the base case population and 
subgroups analysed, including why they were chosen. Page 3-4 
Setting and location 5 State relevant aspects of the system(s) in which the 
decision(s) need(s) to be made. Page 3-4 
Study perspective 6 Describe the perspective of the study and relate this to 
the costs being evaluated. Page 4 
Comparators 7 Describe the interventions or strategies being compared 
and state why they were chosen. Page 5-6 
Time horizon 8 State the time horizon(s) over which costs and 
consequences are being evaluated and say why 
appropriate. Page 4 
Discount rate 9 Report the choice of discount rate(s) used for costs and 
outcomes and say why appropriate. Page 6 
Choice of health 
outcomes 
10 Describe what outcomes were used as the measure(s) 
of benefit in the evaluation and their relevance for the 
type of analysis performed. Page 4 
Measurement of 
effectiveness 
11a Single study-based estimates: Describe fully the design 
features of the single effectiveness study and why the 
single study was a sufficient source of clinical 
effectiveness data. Page 4 
11b Synthesis-based estimates: Describe fully the methods 
used for identification of included studies and synthesis 
of clinical effectiveness data. not applicable 
Measurement and 
valuation of preference 
based outcomes 
12 If applicable, describe the population and methods used 
to elicit preferences for outcomes. 
not applicable 
Estimating resources 
and costs 
13a Single study-based economic evaluation: Describe 
approaches used to estimate resource use associated 
with the alternative interventions. Describe primary or 
secondary research methods for valuing each resource 
item in terms of its unit cost. Describe any adjustments 
made to approximate to opportunity costs. Page 4-5 
13b Model-based economic evaluation: Describe approaches 
and data sources used to estimate resource use 
associated with model health states. Describe primary or 
secondary research methods for valuing each resource 
item in terms of its unit cost. Describe any adjustments 
made to approximate to opportunity costs. not applicable 
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Currency, price date, 
and conversion 
14 Report the dates of the estimated resource quantities 
and unit costs. Describe methods for adjusting estimated 
unit costs to the year of reported costs if necessary. 
Describe methods for converting costs into a common 
currency base and the exchange rate. Page 4 
Choice of model 15 Describe and give reasons for the specific type of 
decision-analytical model used. Providing a figure to 
show model structure is strongly recommended. not applicable 
Assumptions 16 Describe all structural or other assumptions 
underpinning the decision-analytical model. not applicable 
Analytical methods 17 Describe all analytical methods supporting the 
evaluation. This could include methods for dealing with 
skewed, missing, or censored data; extrapolation 
methods; methods for pooling data; approaches to 
validate or make adjustments (such as half cycle 
corrections) to a model; and methods for handling 
population heterogeneity and uncertainty. Page 5-6 
Results 
Study parameters 18 Report the values, ranges, references, and, if used, 
probability distributions for all parameters. Report 
reasons or sources for distributions used to represent 
uncertainty where appropriate. Providing a table to show 
the input values is strongly recommended. Page 6-7 
Incremental costs and 
outcomes 
19 For each intervention, report mean values for the main 
categories of estimated costs and outcomes of interest, 
as well as mean differences between the comparator 
groups. If applicable, report incremental cost-
effectiveness ratios. Page 6-7 
Characterising 
uncertainty 
20a Single study-based economic evaluation: Describe the 
effects of sampling uncertainty for the estimated 
incremental cost and incremental effectiveness 
parameters, together with the impact of methodological 
assumptions (such as discount rate, study perspective). Page 7 
20b Model-based economic evaluation: Describe the effects 
on the results of uncertainty for all input parameters, and 
uncertainty related to the structure of the model and 
assumptions. not applicable 
Characterising 
heterogeneity 
21 If applicable, report differences in costs, outcomes, or 
cost-effectiveness that can be explained by variations 
between subgroups of patients with different baseline 
characteristics or other observed variability in effects that 
are not reducible by more information. not applicable 
Discussion 
Study findings, 
limitations, 
generalisability, and 
current knowledge 
22 Summarise key study findings and describe how they 
support the conclusions reached. Discuss limitations and 
the generalisability of the findings and how the findings 
fit with current knowledge. Page 7-9 
Other 
Source of funding 23 Describe how the study was funded and the role of the 
funder in the identification, design, conduct, and 
reporting of the analysis. Describe other non-monetary 
sources of support. Page 9-10 
Conflicts of interest 24 Describe any potential for conflict of interest of study 
contributors in accordance with journal policy. In the 
absence of a journal policy, we recommend authors 
comply with International Committee of Medical Journal 
Editors recommendations. Page 10 
 
